Home / Online courses / Neuromuscular conditions: overview, management & considerations for therapy in the community - Part 1

Neuromuscular conditions: overview, management & considerations for therapy in the community - Part 1

Member: AUD 30.00 inc. GST

Non-Member: AUD 50.00 inc. GST

Add to cart
  • Overview

This is the first of a two part lecture series exploring neuromuscular conditions and best practice guidelines for supporting and treating children with neuromuscular conditions in the community. These lectures are presented by Karen Herbert, the senior neuromuscular physiotherapist at the Sydney Children's Hospital Neuromuscular Clinic.

This first lecture discusses an overview of Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA) and myotonic dystrophy. The lecture also explores the trajectory and natural progression of neuromuscular conditions and key things to consider in treatment planning for children with neurological conditions.

The second lecture held on the 19th of July explores topics raised in questions following this first lecture.

 

Presenter

Karen Herbert works as Team Lead Physiotherapist – neurology and as a research physiotherapist with the neurology team at SCH. She sees children in the multidisciplinary Sydney Children's Hospital Neuromuscular Clinic, in clinical trails as well as participating with in-house research. As part of her clinical role, Karen oversees the management of children and adolescents with a range of muscle and nerve disorders including neuropathies, muscular dystrophies including congenital myopathies, myotonic dystrophy and Duchenne Muscular Dystrophy. SCH has a large group of children with Spinal Muscular Atrophy and has been involved in several clinical trials and produced real world research articles made possible after advocating for SMA to be added to newborn screening in ACT and NSW.

Karen’s involvement in research has lead to her being involved in several published papers about the changing landscape in Spinal Muscular Atrophy. She currently plays a crucial role in providing the expertise to measure change in these children and is familiar with many functional assessments in clinical trials.

 

Host

Paediatric and Disability National Groups

 

Date of Live Event

05/07/2023

 

CPD Hours

1.0 Hours

 

Please note: The content of this Lecture on Demand (LOD) was captured via a recording of a live lecture at the APA premises. Due to the nature of the event and the recording method, this LOD may not have captured some of the questions/comments from live audience. Your purchase of this module indicates your acceptance of this.

YOU MAY ALSO LIKE